Clin. exp. Immunol. (1979) 38, 92-98.
Serum associated leucocyte locomotion inhibition and leucocyte motility in malignant melanoma: effect of BCG treatment C. ZIELINSKI, H. PEHAMBERGER, A. T. ENDLER & W. KNAPP Institute of Immunology and Department of Dermatology I, University of Vienna, Vienna, Austria
(Accepted for publication 2 March 1979)
SUMMARY
Serum-associated leucocyte locomotion inhibition (SALLI) and leucocyte motility were investigated in patients with malignant melanoma. Ten days after tumour excision twelve out of eighteen patients' sera exhibited a SALLI exceeding the normal range of 15%. The mean SALLI thus reached was 59 2±5 2%. No correlation was observed between SALLI and the level of invasion or the stage of the disease. Six patients selected at random who had a mean SALLI of 71-54±58% after tumour excision were further treated by BCG immunotherapy and presented after 8&2±2-9 months of therapy with a significantly (P< 0.01) lower SALLI of 32-6+8-1%. In eight patients treated exclusively by surgical excision, SALLI remained basically unchanged in the course of 10±2-8 months
(29-0±8*0% vs 30*4±12-9%). The mean index of leucocyte locomotion (LL) of eight melanoma patients who had received BCG for 11-2±2-3 months was 5-9±0 9 cells/field and thus significantly (P
Serum associated leucocyte locomotion inhibition and leucocyte motility in malignant melanoma: effect of BCG treatment C. ZIELINSKI, H. PEHAMBERGER, A. T. ENDLER & W. KNAPP Institute of Immunology and Department of Dermatology I, University of Vienna, Vienna, Austria
(Accepted for publication 2 March 1979)
SUMMARY
Serum-associated leucocyte locomotion inhibition (SALLI) and leucocyte motility were investigated in patients with malignant melanoma. Ten days after tumour excision twelve out of eighteen patients' sera exhibited a SALLI exceeding the normal range of 15%. The mean SALLI thus reached was 59 2±5 2%. No correlation was observed between SALLI and the level of invasion or the stage of the disease. Six patients selected at random who had a mean SALLI of 71-54±58% after tumour excision were further treated by BCG immunotherapy and presented after 8&2±2-9 months of therapy with a significantly (P< 0.01) lower SALLI of 32-6+8-1%. In eight patients treated exclusively by surgical excision, SALLI remained basically unchanged in the course of 10±2-8 months
(29-0±8*0% vs 30*4±12-9%). The mean index of leucocyte locomotion (LL) of eight melanoma patients who had received BCG for 11-2±2-3 months was 5-9±0 9 cells/field and thus significantly (P
